Becton, Dickinson and Company (NYSE:BDX) Stock Position Raised by True Wealth Design LLC

True Wealth Design LLC boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 174.4% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 214 shares of the medical instruments supplier’s stock after acquiring an additional 136 shares during the period. True Wealth Design LLC’s holdings in Becton, Dickinson and Company were worth $52,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BDX. Livelsberger Financial Advisory acquired a new position in Becton, Dickinson and Company during the 3rd quarter valued at approximately $26,000. Ashton Thomas Securities LLC bought a new stake in Becton, Dickinson and Company in the third quarter valued at $33,000. Tompkins Financial Corp boosted its holdings in shares of Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 46 shares during the period. Sound Income Strategies LLC grew its position in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares during the last quarter. Finally, Kennebec Savings Bank acquired a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth about $46,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $221.90 on Friday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $249.89. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The firm has a 50-day moving average of $234.16 and a two-hundred day moving average of $234.12. The company has a market capitalization of $64.14 billion, a price-to-earnings ratio of 37.36, a PEG ratio of 1.65 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating the consensus estimate of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the business earned $3.42 earnings per share. As a group, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be given a $1.04 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend is Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.87%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 63.97%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI increased their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.